Health
Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant sc vs iv trastuzumab – MD Linx
MDLinx original journal summary on Breast Cancer, Oncology from The Breast
Researchers investigated cardiotoxicity related to subcutaneous (s.c.) vs intravenous (i.v.) trastuzumab treatment of early-stage, HER2-positive breast cancer in a real-world population as well as tried to define its predisposing factors. Data for 363 adult patients managed with adjuvant trastuzumab for HER2-positive breast cancer were analyzed retrospectively. It was found that i.v. administration conferred a higher cardiotoxicity rate vs s.c. formulation, and especially in cases with cardiovascular…
-
General18 hours agoIran’s currency at record low as tensions run high
-
Noosa News24 hours agoDisaster relief packages announced for flood-stricken western Queensland
-
Noosa News23 hours agoHundreds pack neighbourhood for no-reserve auction of ready-made charity home
-
General11 hours agoTexas opens probe into Kellogg’s health claims, dyes